Earlier this year, Joe Rogan, host of “The Joe Rogan Experience” podcast, sent a text to President Donald Trump.
FDA has issued a draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for some cancer pharmaceuticals.
Is psilocybin heading to a cancer clinic near you?
Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
FDA has approved Ambelvist (gadoquatrane), an intravenous macrocyclic gadolinium-based contrast agent indicated for contrast-enhanced magnetic resonance imaging to detect and visualize lesions with abnormal vascularity in the central nervous system and non-CNS body regions in adult and pediatric patients, including term neonates.
FDA has accepted for review Genentech’s supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq) for the treatment of patients with stage 3 colon cancer with deficient deoxyribonucleic acid mismatch repair.
FDA is warning providers about the interruptions in the supply of stereotactic breast biopsy needles because of recent supplier issues. The manufacturing disruption in supply of these devices is expected to impact patient care and may require adjustments to the clinical management of patients indicated to undergo a breast biopsy.
The oncology field is confronting three forces simultaneously.
Thyme Care announced the expansion of its Next Chapter Care survivorship program to more than 15,000 members, addressing a challenge that often receives less attention in cancer care: what happens after treatment ends.
